CRISPR-Cas as a Versatile Platform for Cancer Research, Screening, and Therapeutic Development
This review discusses CRISPR-Cas9 applications in oncology including functional genomic screens to discover and validate therapeutic targets, generation of preclinical cancer models, and emerging uses in cancer detection assays. The authors highlight how CRISPR-based genetic screens can systematically identify drug resistance mechanisms and novel diagnostic biomarkers for clinical translation.
The original study
CRISPR-Cas: a tool for cancer research and therapeutics.
- Authors
- Yin H, Xue W, Anderson DG
- Journal
- Nature reviews. Clinical oncology
- Type
- Journal Article, Research Support, Non-U.S. Gov't, Review
- PMID
- 30664678
Original abstract
In the past decade, the development of a genome-editing technology mediated by CRISPR has made genetic engineering easier than ever, both in vitro and in vivo. CRISPR systems have enabled important advances in cancer research by accelerating the development of study models or as a tool in genetic screening studies, including those aiming to discover and validate therapeutic targets. In this Review, we discuss these applications as well as new potential uses of CRISPR to assist in cancer detection or the development of anticancer therapies.